13.32
price down icon5.36%   -0.755
after-market Handel nachbörslich: 12.19 -1.13 -8.48%
loading

Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten

pulisher
12:50 PM

Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths - The New York Times

12:50 PM
pulisher
Jul 21, 2025

Sarepta stops Elevidys shipments after standoff with FDA - BioPharma Dive

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta to pause gene therapy Elevidys shipments in U.S. - CNBC

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta (SRPT) Announces Voluntary Pause of Elevidys Shipments in US - Bloomberg.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta halts US shipments of Duchenne therapy, bowing to FDA - Endpoints News

Jul 21, 2025
pulisher
Jul 21, 2025

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy - statnews.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta to pause gene therapy Elevidys shipments in US - TradingView

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta bows to FDA pressure, pulls Duchenne therapy from market - NBC Boston

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. - Sarepta Therapeutics

Jul 21, 2025
pulisher
Jul 21, 2025

About Face: Sarepta to Pause Elevidys Shipments Temporarily - Genetic Engineering and Biotechnology News

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta’s Elevidys Halted at Children’s Hospital Los Angeles - Bloomberg.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta under pressure: FDA requests halt of Elevidys shipments - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, HC Wainwright Says - Bloomberg.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA - Investor's Business Daily

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy - The Columbus Dispatch

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear - statnews.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta shares cut to $0 at H.C. Wainwright (SRPT:NASDAQ) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 21, 2025

Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths - MedPage Today

Jul 21, 2025
pulisher
Jul 21, 2025

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis - BioPharma Dive

Jul 21, 2025
pulisher
Jul 21, 2025

Navigating the Crossroads of Innovation and Safety: Assessing Sarepta Therapeutics in the Gene Therapy Landscape - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta refuses to pull gene therapy despite FDA order - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy - Fierce Biotech

Jul 21, 2025
pulisher
Jul 21, 2025

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse. - Barron's

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug - Investopedia

Jul 21, 2025
pulisher
Jul 21, 2025

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Piper Sandler lowers Sarepta Therapeutics stock price target on Elevidys concerns - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - TradingView

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Therapeutics: Why Is SRPT Stock Crashing? - Forbes

Jul 21, 2025
pulisher
Jul 21, 2025

Cambridge-based gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - WBUR

Jul 21, 2025
pulisher
Jul 21, 2025

Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - Morningstar

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Faces FDA Hold on Gene Therapy Trials - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

FDA places clinical hold on Sarepta’s gene therapy trials for muscular dystrophy - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta slides as FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Therapeutics stock rating reiterated at Hold by TD Cowen - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Therapeutics stock price target slashed to $0 by H.C. Wainwright - Investing.com Nigeria

Jul 21, 2025
pulisher
Jul 21, 2025

SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline - Newsfile

Jul 21, 2025
pulisher
Jul 21, 2025

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT) - StreetInsider

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta extends losses premarket after refusing FDA’s halt request (SRPT:NASDAQ) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 21, 2025

BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT) - StreetInsider

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta stock extends decline as company declines FDA call to withdraw drug - MarketWatch

Jul 21, 2025
pulisher
Jul 21, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at Needham & Company LLC - Defense World

Jul 21, 2025
pulisher
Jul 21, 2025

Oppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $41.00 - Defense World

Jul 21, 2025
pulisher
Jul 21, 2025

Bank of America Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00 - Defense World

Jul 21, 2025
pulisher
Jul 21, 2025

Leerink Partnrs Has Pessimistic Outlook of SRPT Q2 Earnings - Defense World

Jul 21, 2025
pulisher
Jul 21, 2025

What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia

Jul 21, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics Crashes After A Third Gene Therapy Patient Dies - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 20, 2025
pulisher
Jul 20, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News

Jul 20, 2025
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Kapitalisierung:     |  Volumen (24h):